FTC urges Texas regulators to block CHS’ divestiture of 2 hospitals

Alia Paavola Becker’s Healthcare

The Federal Trade Commission is urging Texas regulators to block Franklin, Tenn.-based Community Health Systems’ planned divestiture of two hospitals in the state.

In April, CHS announced its intent to sell the 231-bed Abilene (Texas) Regional Medical Center to Abilene-based Hendrick Health System and its 171-bed San Angelo (Texas) Community Medical Center to Shannon Health System in San Angelo. 

The Texas Health and Human Services Commission ultimately will approve or block the proposed transactions as Texas implemented a law that shields the deals from federal oversight in exchange for state oversight.

In a letter to the Texas commission, the FTC argues that if the deals are allowed to move forward, the combinations would remove competition in the markets, resulting in higher prices and harming consumers.

Particularly, if Hendrick Health System is allowed to purchase Abilene Regional, the combined organization would have an 85 percent market share of inpatient services in the region, the FTC said. 

“Hendrick competes vigorously with Abilene Regional to be included in health plan networks and to attract patients. The proposed Hendrick merger would eliminate this competition and would likely lead to increased prices and reduced quality and availability of healthcare services in Midwest Texas,” the FTC wrote in the letter. 

In addition, the FTC argues that if the divestiture of San Angelo Community Medical Center to Shannon Health moves forward, the combined organization will have a 62.3 percent market share of inpatient hospital services and would have concentration numbers that “approach monopoly levels.”

Read the full letter here

States ranked by COVID-19 test positivity rates: Sept. 2

Molly Gamble (Twitter) – Tuesday, July 14th, 2020 Print  | EmailShare  

Here are the rates of positive COVID-19 tests in each state, along with the number of new cases most recently reported and number of tests conducted per 1,000 people. 

Data points were last updated Sept. 2. Data for positivity rates and tests are seven-day moving averages; new cases are daily counts as reported by state and the District of Columbia. The information cited is from the Johns Hopkins Coronavirus Resource Center. States are arranged in descending order of test positivity rates. 

Editor’s note: A jurisdiction might report a negative number of probable cases on a given day if more probable cases were disproven than were initially reported on that day. Furthermore, some states modify their reporting to include both confirmed cases and probable cases, which may cause new case data to spike. Due to limited reporting on Sundays, some data is unavailable until later hours Monday, including new daily cases.

Alabama: 32.8 percent positive

New daily cases: 1,558

Tests per 1,000: 0.9

South Dakota: 22.2 

New daily cases: 240

Tests per 1,000: 1.6

North Dakota: 20.1

New daily cases: 184

Tests per 1,000: 1.7

Iowa: 18.5

New daily cases: 708

Tests per 1,000: 1.6

Kansas: 16

New daily cases: 363

Tests per 1,000: 1.3

Nevada: 15.3

New daily cases: 405

Tests per 1,000: 1

Mississippi: 14.5

New daily cases: 634

Tests per 1,000: 1.5

Missouri: 13.6

New daily cases: 1,103

Tests per 1,000: 1.6

South Carolina: 13.2

New daily cases: 854

Tests per 1,000: 1.3

Florida: 12.2

New daily cases: 7,569

Tests per 1,000: 1.4

Idaho: 11.5

New daily cases: 272

Tests per 1,000: 1.4

Georgia: 10.4

New daily cases: 2,226

Tests per 1,000: 1.9

Nebraska: 9.9

New daily cases: 287

Tests per 1,000: 1.7

Texas: 9.9

New daily cases: 4,982

Tests per 1,000: 1.5

Minnesota: 9.4

New daily cases: 491

Tests per 1,000: 1.5

Oklahoma: 9.3

New daily cases: 665

Tests per 1,000: 2.0

Indiana: 8.9

New daily cases: 695

Tests per 1,000: 1.5

Wisconsin: 8.8

New daily cases: 981

Tests per 1,000: 1.5

Hawaii: 8.6

New daily cases: 181

Tests per 1,000: 1.7

Kentucky: 8.4

New daily cases: 789

Tests per 1,000: 1.8

Utah: 7.8

New daily cases: 296

Tests per 1,000: 1.5

Tennessee: 7.6

New daily cases: 1,396

Tests per 1,000: 3

Arkansas: 7.3

New daily cases: 273

Tests per 1,000: 2.7

Virginia: 7.1

New daily cases: 1,018

Tests per 1,000: 1.7

Arizona: 6.6

New daily cases: 507

Tests per 1,000: 0.9

North Carolina: 6

New daily cases: 2,115

Tests per 1,000: 2.6

Montana: 5.6

New daily cases: 88

Tests per 1,000: 2.1

Louisiana: 5

New daily cases: 689

Tests per 1,000: 2.9

California: 4.9

New daily cases: 3,142

Tests per 1,000: 2.6

Pennsylvania: 4.8

New daily cases: 753

Tests per 1,000: 1.1

Oregon: 4.6

New daily cases: 233

Tests per 1,000: 1.1

Maryland: 4.6

New daily cases: 614

Tests per 1,000: 2

Delaware: 4.4

New daily cases: 106

Tests per 1,000: 1.9

Illinois: 4.4

New daily cases: 1,492

Tests per 1,000: 3.5

Wyoming: 3.8

New daily cases: 24

Tests per 1,000: 1.5

Ohio: 3.4

New daily cases: 1,451

Tests per 1,000: 3

Colorado: 3.3

New daily cases: 351

Tests per 1,000: 1.5

West Virginia: 3.2

New daily cases: 264

Tests per 1,000: 2.8

Washington: 3.2

New daily cases: 304

Tests per 1,000: 1.7

Michigan: 2.5

New daily cases: 795

Tests per 1,000: 3

New Mexico: 2.4

New daily cases: 108

Tests per 1,000: 2.5

Washington, D.C.: 1.7

New daily cases: 57

Tests per 1,000: 4.3

Massachusetts: 1.6

New daily cases: 355

Tests per 1,000: 3.1

New Jersey: 1.4

New daily cases: 330

Tests per 1,000: 2.6

Rhode Island: 1.2

New daily cases: 53

Tests per 1,000: 6.9

Alaska: 1.2

New daily cases: 34

Tests per 1,000: 7.9

New Hampshire: 1.1

New daily cases: 22

Tests per 1,000: 1.2

Connecticut: 0.9

New daily cases: 127

Tests per 1,000: 4.4

New York: 0.8

New daily cases: 754

Tests per 1,000: 4.3

Maine: 0.6

New daily cases: 20

Tests per 1,000: 3.3

Vermont: 0.4

New daily cases: 11

Tests per 1,000: 3.7

Henry Ford researchers defend hydroxychloroquine study, slam politics surrounding drug

Gabrielle Masson 

The persisting political climate has made any objective discussion about hydroxychloroquine “impossible,” two Henry Ford Health System executives wrote in an open letter dated Aug. 3.

Adnan Munkarah, MD, executive vice president and chief clinical officer at the Detroit-based system, along with Steven Kalkanis, MD, senior vice president and chief academic officer for Henry Ford, penned the letter in response to comments by Anthony Fauci, MD, director of the National Institute of Allergy and Infectious Diseases, that their study on hydroxychloroquine was “flawed.” 

The situation is a bellwether for the kind of tension other systems may face when their clinical research overlaps with commentary from the White House. 

Four things to know:

1. Addressing friends and colleagues around the world, Dr. Munkarah and Dr. Kalkanis said the most accepted and definitive way to determine treatment efficacy is a double-blind, randomized clinical trial. But this type of study takes a long time to design, execute and analyze, so observational research is used to get as best an answer as soon as possible.

2. Observational research can never completely account for biases inherent in how physicians make different decisions to treat different patients, the leaders said. It’s not unusual that results vary in different studies, and no one study should be considered on its own.

3. The Henry Ford treatment study should be considered as another important contribution to hydroxychloroquine research, Drs. Munkarah and Kalkanis wrote in a letter to the editor published in the International Journal of Infectious Diseases July 31. Based on their findings, the authors believe the drug can have a role in reducing mortality for COVID-19.

4. Scientific debate is common, and can, in part, fuel the advancement of knowledge, the leaders write. They said their only goal was to report validated findings and allow the science to speak for itself, regardless of political considerations. In light of the recent events, Drs. Munkarah and Kalkanis said they have decided to no longer comment about the topic outside of the medical community and will stay focused on their patients, community and commitment to clinical and academic integrity

https://www.beckershospitalreview.com/hospital-management-administration/henry-ford-researchers-defend-hydroxychloroquine-study-slam-politics-surrounding-drug.html

Coronavirus or West Nile? CDC reports 17 cases of mosquito disease that present symptoms similarly to COVID-19

By Amy McGorry | Fox News

‘Mosquitoes do not carry COVID, but because the symptoms are so similar you’ll need to talk with your doctor ‘

While the United States deals with the coronavirus, the West Nile virus is on the rise and can show similar features to COVID-19, creating some confusion. Seventeen human cases of West Nile virus have been reported so far in Texas, Los Angeles County, and Fla., according to the Centers for Disease Control and Prevention (CDC).

In Georgia, Fox 5 Atlanta reported this week that mosquitos positive for West Nile Virus were found in DeKalb County.  Because the symptoms are similar to COVID-19, which is still running rampant throughout the country, health experts warn to not overlook West Nile when diagnosing.

“Mosquitoes do not carry COVID, but because the symptoms are so similar you’ll need to talk with your doctor to see about getting a COVID test,” Juanette Willis, with the DeKalb County Board of Health, told FOX 5.

BLOOD TEST IDENTIFIES WHICH CORONAVIRUS PATIENTS MAY BE HELPED OR HARMED BY STEROID TREATMENT

Dr. Paul Auwaerter, clinical director of the division of infectious diseases at Johns Hopkins Hospital, told Yahoo Life regarding West Nile infections, “About 20 percent might develop a flu-like illness [also known as West Nile fever] that is probably indistinguishable from COVID-19. “ The professor of medicine at John Hopkins University School of Medicine also told the media outlet: “They can have headache, fever, muscle aches, gastrointestinal symptoms [vomiting and diarrhea], and swollen lymph glands.”

Auwaerter said in the article with the diseases sharing similar characteristics, “People are just assuming they have COVID-19,” rather than a mosquito bearing disease.  “Statistically, it’s probably true that it’s COVID in these cases,” the article cited Auwaerter, “But it’s not always the case.”

Health officials at Cleveland clinic, according to the media outlet, stated a skin rash on the trunk and chest, can occur with the West Nile virus while it is not as typical with COVID-19 patients who, if they do present with a rash, typically report it on their toes.

Both diseases can have detrimental effects on a person’s health and can affect the nervous system, according to the CDC, which also states on its website that nearly “1 in every 150 people who are infected with West Nile disease can develop a severe illness affecting the central nervous system” such as encephalitis (brain inflammation) or meningitis (inflammation of the brain and spinal cord). Doctors told Fox News, in some cases of West Nile infections, patients can show symptoms including high fever, stiff neck, severe headache, and can even become confused, weak and experience possible seizures.

DOGS ABLE TO SNIFF CORONAVIRUS IN HUMAN SALIVA, GERMAN STUDY FINDS

The novel coronavirus can also show neurological effects. Some cases reported peripheral neuropathy in the legs and complaints of “brain fog,” some physicians explained to Fox News. COVID-19 can also affect the trigeminal and olfactory nerves which affect the sense of smell. which is not typical with the West Nile infection. Besides those symptoms, neurologists told Fox News that coronavirus can present with headache, difficulty focusing, blood clotting, weakness and some studies are linking it with the neurological condition Guillain-barre.

One main difference, according to health experts, is that the coronavirus is a contagious respiratory disease where West Nile is not. The West Nile illness is contracted typically by a mosquito bite, while novel coronavirus is currently believed to spread through sneezing, coughing or touching, according to the CDC. To differentiate clinically between the two illnesses, a physician can perform a nasal swab test to detect novel coronavirus while a blood test can determine if a person has been infected with the West Nile virus infection.

Texas hospital CEO: COVID inpatient count ‘misinterpreted,’ level of alarm ‘unwarranted’

By Daniel Payne June 25th 2020

Health officials in Texas are logging every single COVID-19-positive hospital patient in the state as a COVID-19 hospitalization, even if the patients themselves are admitted seeking treatment for something other than the coronavirus. 

That policy may be serving to artificially inflate what ostensibly seems like a significant COVID-19 surge in the state. Texas has lately been the focal point of national anxiety over concerns that a “second wave” of the coronavirus has begun there after the state began reopening nearly two months ago. 

COVID-19 hospitalizations there have been on a steady upward track for about the last two weeks, per the state’s coronavirus dashboard, which on Thursday recorded about 4,400 coronavirus hospitalizations in the state. But at least part of that trend may be due to liberal coding policies by state officials. 

Lindsey Rosales, a spokeswoman for the Texas Department of State Health Services, confirmed to Just the News this week that the state is categorizing every inpatient in the state with a positive COVID-19 test as a COVID-19 hospitalization. 

“The number of hospitalized patients includes patients with a lab-confirmed case of COVID-19 even if the person is admitted to the hospital for a different reason,” Rosales said. 

Asked if inpatients in the state are tested for COVID-19 whenever they arrive for treatment, Rosales said, “Hospitals set their own protocols for determining when and if to test patients for COVID-19.”

She said the state does not keep track of the patients hospitalized with the coronavirus versus those hospitalized specifically because of it. 

Texas Health Resources, one of the state’s largest hospital systems, says on its website that its “patients [are] tested before most procedures.” Elective surgeries and other medical procedures in Texas have gone up in recent weeks as the state has gradually re-opened following its lockdown. 

Amid worry, major hospital leaders stress calm

Queries to multiple Texas hospital officials this week went unanswered. But leaders of several major hospitals in Houston this week urged the public to remain calm, suggesting that the extent of the outbreak has been overstated. 

At a virtual press conference on Thursday, the chief executives of Houston Methodist, Memorial Hermann Health System, St. Luke’s Health, and Texas Children’s hospitals stated that their hospitals are well-prepared to handle an even greater increase in patients than that which has emerged over the past few weeks. 

The number of hospitalizations are “being misinterpreted,” said Houston Methodist CEO Marc Boom, “and, quite frankly, we’re concerned that there is a level of alarm in the community that is unwarranted right now.”

“We do have the capacity to care for many more patients, and have lots of fluidity and ability to manage,” Boom said.

He pointed out that his hospital one year ago was at 95% ICU capacity, similar to the numbers the hospital is seeing today. “It is completely normal for us to have ICU capacities that run in the 80s and 90s,” he said. “That’s how all hospitals operate.” 

He noted that around 25% of ICU patients are COVID-19-positive. But the hospital “[has] many levers in our ability to adjust our ICU,” he said, claiming that the hospital capacity regularly reported by the media is “base” capacity rather than surge capacity. 

Texas Children’s Hospital CEO Mark Wallace added that his facility has “a lot of capacity.”

“We have the ability to take care of all of the Houstonians that need a critical care environment, that need to be operated on, or acute care,” Wallace said.

“There is not a scenario, in my opinion, where the demand for our beds … would eclipse our capability,” he continued. “I cannot imagine that. I just cannot.”

As of Thursday afternoon, Texas had around 13,000 open hospital beds statewide. 

https://justthenews.com/politics-policy/coronavirus/texas-government-counting-every-covid-positive-hospital-case

Texas Governor Hits ‘Pause’ On Further Reopening Amid COVID-19 Surge

June 25, 2020 by Laurel Wamsley

Updated at 12:45 p.m. ET

Texas Gov. Greg Abbott has announced the state will “pause” any further reopening of its economy for now, a day after he said that Texas is facing a “massive outbreak” of the coronavirus.

“As we experience an increase in both positive COVID-19 cases and hospitalizations, we are focused on strategies that slow the spread of this virus while also allowing Texans to continue earning a paycheck to support their families,” Abbott said in a statement Thursday morning. “The last thing we want to do as a state is go backwards and close down businesses. This temporary pause will help our state corral the spread until we can safely enter the next phase of opening our state for business.”

Texas was among the first states to begin the process of reopening, and many businesses are in operation once again. Those businesses that are already permitted to be open may continue to operate under the existing health protocols and capacity restrictions. Bars and restaurants have already opened for indoor seating, and gymsmalls and movie theaters have been allowed to open, too.

Nearly 90,000 Texans filed for unemployment last week, NPR member station KUT reported — about 5,480 ​fewer new claims than the previous week.

Abbott also halted elective surgeries in four of the state’s largest counties. That move is aimed at expanding hospital capacity as the spike in hospitalizations threatens to overwhelm intensive care units and outstrip available ventilators.

His order suspends elective surgeries at hospitals in Bexar, Dallas, Harris and Travis counties — home to the respective cities of San Antonio, Dallas, Houston and Austin. It directs hospitals in those counties to “postpone all surgeries and procedures that are not immediately, medically necessary to correct a serious medical condition or to preserve the life of a patient who without immediate performance of the surgery or procedure would be at risk for serious adverse medical consequences or death, as determined by the patient’s physician.”

Abbott said he may add or subtract counties from the list as needs arise.

In San Antonio, ventilator availability dipped below 70% for the first time on Wednesday, Texas Public Radio reported. In Houston, one hospital’s ICU reportedly was at 120% capacity, while another one’s was at 88%.

Texas Medical Center in Houston said Tuesday that 97% of its ICU beds were occupied and that 27% of those patients were people who had tested positive for the coronavirus. It said its normal ICU occupancy is 70% to 80%. On Thursday, the Houston Chronicle reported that the medical center has reached 100% of its ICU capacity.

On Wednesday the state reported 5,551 new coronavirus cases, its highest daily figure yet. Twenty-nine new COVID-19 deaths were reported, with cumulative fatalities in the state now numbering 2,249.

Just nine days ago, Abbott touted the state’s “abundant” hospital capacity as the numbers of cases in the state were rising quickly. According to state data, as of Wednesday, the Dallas area had 1,130 people hospitalized with COVID-19, Houston had 1,342, San Antonio had 549, and Austin had 274.

“These four counties [Bexar, Dallas, Harris and Travis] have experienced significant increases in people being hospitalized due to COVID-19 and today’s action is a precautionary step to help ensure that the hospitals in these counties continue to have ample supply of available beds to treat COVID-19 patients,” Abbott said in Thursday’s statement.

“As we work to contain this virus, I urge all Texans to do their part to help contain the spread by washing their hands regularly, wearing a mask, and practicing social distancing.”

https://www.npr.org/sections/coronavirus-live-updates/2020/06/25/883311877/texas-governor-hits-pause-on-further-reopening-amid-covid-19-surge

Texas stops reopening amid surge in COVID-19

Texas Governor Greg Abbott announced that reopening will be paused as the state is seeing a major surge in COVID-19 cases.

The state reported 5,500 cases in a single day this week. Over 125,000 cases of COVID-19 have been reported in the state since the outbreak began.

Texas is one of many states seeing a massive uptick in COVID-19 cases. Arizona and Florida are also seeing major rises with each state seeing record numbers of cases this week.

California is also seeing a surge in cases with over 5,000 daily cases reported this week.

In all, 26 states are seeing some increase in COVID-19 cases.

While Abbott announced a pause in reopenings due to the disease, he said that he will not reimplement shutdowns.

“The last thing we want to do as a state is go backwards and close down businesses,” Governor Abbott said in a statement. “This temporary pause will help our state corral the spread until we can safely enter the next phase of opening our state for business. I ask all Texans to do their part to slow the spread of COVID-19 by wearing a mask, washing their hands regularly, and socially distancing from others.”

https://www.healthline.com/health-news/coronavirus-live-updates

CDC: Coronavirus Fatality Rate 0.26%, 8-15x Lower than Estimates

EDWIN MORA 27 May 2020

Data from the U.S. Centers of Disease Control and Prevention (CDC) suggests that the novel coronavirus’s true fatality rate in the United States, which takes into account mild and asymptomatic cases, stands at 0.26 percent, about eight to 15 times lower than earlier mortality rate estimates of between two and four percent, which prompted the lockdowns.

However, the true (or infection) mortality rate is more than double the flu’s 0.1 percent.

The case (or crude) fatality rate only takes into account confirmed coronavirus cases, excluding people with mild or no symptoms that do not require medical attention.

Meanwhile, the infection fatality rate (IFR) accounts for the estimated number of mild and asymptomatic cases. It tends to be lower than the crude fatality ratio because it shows that more people have contracted the virus without dying.

The 0.26 percent mortality rate (about three in 1,000) linked to COVID-19, the disease produced by the coronavirus, is lower than the death rate predicted by the infamous Imperial College report and other assessments that prompted the lockdowns across America.

Using data contained in a CDC report, last reviewed on May 20, Daniel Horowitz, a senior editor at Conservative Review (CR), noted in an editorial this month:

For the first time, the CDC has attempted to offer a real estimate of the overall death rate for COVID-19, and under its most likely scenario, the number is 0.26%. Officials estimate a 0.4% fatality rate among those who are symptomatic and project a 35% rate of asymptomatic cases among those infected, which drops the overall infection fatality rate (IFR) to just 0.26% — almost exactly where Stanford researchers pegged it a month ago.

Ultimately, we might find out that the IFR is even lower because numerous studies and hard counts of confined populations have shown a much higher percentage of asymptomatic cases. Simply adjusting for a 50% asymptomatic rate would drop their fatality rate to 0.2% – exactly the rate of fatality Dr. John Ionnidis of Stanford University projected.

Breitbart News and other analysts verified Horowitz’s calculations.

By taking into account mild and asymptomatic cases that were not clinically confirmed, some health analysts have determined that COVID-19 is more widespread but less deadly than early estimates suggested.

Health experts have noted that the faster the disease spreads and hits its peak, the fewer people will die.

In early March, the World Health Organization (W.H.O.), a United Nations component, explained the difference between the crude and infection mortality rates, noting:

Mortality for COVID-19 appears higher than for influenza, especially seasonal influenza. While the true mortality of COVID-19 will take some time to fully understand, the data we have so far indicate that the crude mortality ratio (the number of reported deaths divided by the reported cases) is between 3-4%, the infection mortality rate (the number of reported deaths divided by the number of infections) will be lower. For seasonal influenza, mortality is usually well below 0.1%.

In April, the CDC reportedly placed the crude fatality case at around four percent.

Ultimately, the W.H.O. placed the globe’s crude mortality rate at 3.4 percent. Early in the outbreak, health officials, including Dr. Anthony Fauci from the White House Coronavirus Task Force, had concluded that the crude mortality stood at about two percent.

Fauci is the top infectious disease expert in the United States. There is a patchwork of policies across the U.S. for how to count the number of coronavirus deaths, meaning that the total fatality figure could be higher or lower than the actual number, depending on the state.

Beckman Coulter awarded expanded partnership with BARDA to assess sepsis diagnostic and prediction algorithm with COVID-19 patients

Brea, Calif., May 15, 2020

Beckman Coulter today announced it was awarded an expanded partnership with BARDA as part of their rapidly expanding COVID-19 medical countermeasure portfolio. The partnership was awarded to Beckman Coulter, in collaboration with Dascena, Inc., for additional advanced research and development toward optimization of a machine-learning based sepsis diagnostic and prediction algorithm to include assessing its use with coronavirus (COVID-19) patients.

The sepsis diagnostic and prediction algorithm builds on Beckman Coulter’s existing Early Sepsis Indicator, which received FDA 510(k) clearance in April 2019, combining the monocyte distribution width (MDW) novel laboratory test parameter values with Dascena’s electronic health record data based machine-learning algorithm to help accurately predict and detect those with sepsis.

“Until recently, the majority of sepsis cases have been thought to be caused by bacterial pathogens,” said Shamiram R. Feinglass, M.D., MPH, chief medical officer, Beckman Coulter. “COVID-19 is changing that, and causing a paradigm shift in how we think about sepsis. The aim of the study is to determine whether MDW, as part of the sepsis prediction algorithm, will be able to aid in the detection of sepsis regardless of whether it is bacterial or viral-induced.”

“The global impact that COVID-19 has had on the health system is undeniable. It has changed the way the industry thinks about so many things, and sepsis is no exception,” said Peter Soltani, Ph.D., senior vice president and general manager of the hematology business unit at Beckman Coulter. “Beckman Coulter is deeply committed to the fight against COVID-19 and has been working diligently to quickly bring quality SARS-CoV-2 serology assays to the market. We are thrilled to expand our partnership with BARDA, so we can extend that commitment to our sepsis research and begin clinical trials that include COVID-19 patients.”

“We are excited to deepen our partnership with Beckman Coulter to help respond to the global pandemic that has exacerbated the challenge of sepsis, a condition that already kills an American every two minutes,” said Jana Hoffman, Ph.D., vice president of science at Dascena.

This COVID-19 specific study is part of BARDA’s Rapidly Deployable Capabilities program to identify and pilot near-term innovative solutions for COVID-19, leveraging the development of Beckman Coulter’s digital sepsis prediction algorithm under BARDA’s Division of Research Innovation and Venture’s (DRIVe’s) Solving Sepsis Program.

For more information on Beckman Coulter’s Early Sepsis Indicator, visit www.beckmancoulter.com/sepsis. For more information on BARDA’s rapidly-expanding COVID-19 medical countermeasure portfolio, visit BARDA’s COVID-19 Portfolio.

About Beckman Coulter
Beckman Coulter is committed to advancing healthcare for every person by applying the power of science, technology and the passion and creativity of our teams to enhance the diagnostic laboratory’s role in improving healthcare outcomes. Our diagnostic systems are used in complex biomedical testing, and are found in hospitals, reference laboratories and physician office settings around the globe. Beckman Coulter offers a unique combination of people, processes and solutions designed to elevate the performance of clinical laboratories and healthcare networks. We do this by accelerating care with a menu that matters, bringing the benefit of automation to all, delivering greater insights through clinical informatics and unlocking hidden value through performance partnership. An operating company of Danaher Corporation (NYSE: DHR) since 2011, Beckman Coulter is headquartered in Brea, Calif., and has more than 11,000 global associates working diligently to make the world a healthier place.

About Dascena
Dascena, Inc. is developing machine learning diagnostic algorithms to enable early disease intervention and improve care outcomes for patients. For more information, visit Dascena.com.

###

Hospitals are paid more for Medicare patients confirmed or presumed to have coronavirus

By Hollie McKay | Fox News

If a Medicare patient is diagnosed with – or even presumed to have contracted — coronavirus, hospitals across the United States are given more money from the federal government to treat that patient, economic assessments show. That amount can as much as triple if the patient requires a ventilator, making some wonder whether there is a financial impetus to overstate coronavirus numbers, with others calling such potential abuse “unlikely.”

Medicare, a long-running federal health insurance program for those aged 65 or over – which also happens to be the most vulnerable demographic for an acute coronavirus infection and mortality – functions by paying hospitals a fixed sum depending on which diagnosis the Medicare Severity Diagnosis Related Group (MS-DRG) it falls under.

“These DRG rates are adjusted each year, and that brings up [one] way in which the government has increased payments to hospitals. Budget rules referred to as sequestration, require across-the-board cuts in Medicare because the federal deficit is so high,” Doug Badger, visiting fellow for domestic policy studies at The Heritage Foundation, told Fox News. “Congress eliminated these across-the-board cuts during the COVID-19 epidemic. That translates to an across-the-board increase in Medicare payments to hospitals for any admission of any Medicare patient, whether or not they have COVID-19.”

However, in the case of COVID-19, the Centers for Medicare & Medicaid Services (CMS) characterizes it under the umbrella of respiratory infections and inflammations, and there are add-ons specific to the illness that was borne out of China late last year and has since infected 1.2 million Americans and claimed the lives of over 70,000.

Recent federal legislation, known as Coronavirus Aid, Relief and Economic Security Act, or CARES Act, has provisions that enable the government to pay more to hospitals specific to the coronavirus pandemic.

“The CARES Act authorized a temporary 20 percent increase in reimbursements from Medicare for COVID-19 patients to account for both anticipated and unanticipated increases in the cost of care for these medically complex patients,” explained Dr. Summer McGee, dean of the School of Health Sciences at the University of New Haven.

As Badger highlighted, instead of getting paid the DRG rate, a hospital that admits a coronavirus patient will receive 20 percent more compensation than they would for providing that same care to a non-coronavirus patient.

“Imagine two Medicare patients, one with COVID-19 and another one not, with pneumonia in the same ICU. Medicare will pay, for example, $10,000 for the pneumonia patient who doesn’t have COVID-19 and $12,000 for the patient who does,” he surmised. “The rationale is that this provides a sort of rough justice method of making sure that hospitals that get a lot of COVID-19 patients also get extra money from the government.”

Moreover, the Act established a $100 billion fund to aid hospitals – of which some $30-$50 billion is “used to reimburse healthcare providers, at Medicare rates, for COVID-related treatment of the uninsured,” the U.S. Department of Health and Human Services (HHS) stated.

Provisions in the act allow for hospitals to receive three times more per patient in need of a ventilator, multiple analyses have confirmed.

According to an April 24 release from the Kaiser Family Foundation, a nonprofit organization focused on American health care issues, HHS increased its allocation from $30 billion to $50 billion to providers.

“Since Medicaid typically reimburses at lower rates than other providers, this methodology could disadvantage providers who see a high proportion of Medicaid patients,” the release stated. “The Terms and Conditions state that this money can be used for ‘health care-related expenses or lost revenues that are attributable to coronavirus.'”

HHS also announced that $10 billion would be set aside for high-impact areas significantly impacted by the coronavirus, emphasizing “that New York hospitals are expected to receive a large share of the funds.”

“This more targeted funding will help address concerns from hospitals in the hardest-hit areas that they had not gotten sufficient funds to help them manage a surge in COVID-19 patients. To help HHS determine which facilities will qualify for this targeted distribution, each hospital must submit the number of ICU beds it has and its total COVID-19 admissions as of April 10, 2020,” Kaiser observed.

On April 14, New York’s overall coronavirus death toll was revised with a major leap – with some 3,700 fatalities added with the provision that the count now included “people who had never tested positive for the virus but were presumed to have it.”

The uptick ignited a sharp rebuke from President Trump the following day, who then hinted that the hardest-hit state was inflating its numbers.

That same day, Sen. Scott Jensen, R-Minn., a Minnesota-based physician, took to his Facebook page to question the reimbursement apparatus.

“How can anyone not believe that increasing the number of COVID-19 deaths may create an avenue for states to receive a larger portion of federal dollars,” he wrote. “Already, some states are complaining that they are not getting enough of the CARES Act dollars because they are having significantly more proportional COVID-19 deaths.”

The issue of the “presumed” cases has proven particularly controversial. While some states such as California and Minnesota document only instances of laboratory-verified coronavirus, other states like New York list assumed cases – which is permissible by the Centers for Disease Control and Prevention (CDC) in circumstances where an individual meets clinical criteria such as displaying symptoms, but a certified test has not been undertaken.

A “presumed” or “probable” coronavirus case can also be listed on a death certificate, as per CDC guidelines.

While Medicare is paying hospital fees for coronavirus cases in ranges well into the thousands per patient – a Kaiser analysis using average Medicare payments calculating as much as $40,218 for a patient needing ventilator support for longer than 96 hours – medical professionals contend that exact amounts differ place by place, hospital by hospital and are not necessarily predetermined. CMS makes an assessment on exactly how much to pay a hospital per coronavirus patient based on the DRG and a range of factors, including the resources available and labor costs to treat the patient.

This, at some point, automatically leads to a larger government check. The Foundation for Economic Education argues that “the economic incentive to add COVID-19 to diagnostic lists and death certificates is clear and does not require any conspiracy.”

“Incentive-based medicine always runs up the bill. Particularly in this environment, no one is going to challenge it,” cautioned Ohio-based physician Dr. Sherri Tenpenny. “Potentially, it could [be exploitative] as hospitals are economically strapped to the point of laying off doctors and nurses.”

But despite some concerns that hospitals – which are struggling nationwide given that most states have shut down elective and non-emergency procedures which needed to keep budgets balanced – there are no reports of flagrant exploitation, exaggerated coronavirus numbers, or evidence that facilities are purporting to profit off the pandemic to collect more in Medicare payments.

“In a crisis like this, the fees for service payments are unlikely to be abused. Long-term hospitalizations with medically complex patients on ventilators cannot be paid with a simple standard sticker price,” McGee asserted. “Hospitals should be paid for the services they are providing at a premium because of the extremely challenging situation they are in.”

She also noted that while hospitals are trying to save critically ill patients in a global pandemic, it is not the time to quibble over reimbursements.

“After the COVID-19 crisis ends, CMS should do a review to determine the costs of care and to ensure that no health care fraud and abuse took place,” McGee added.